|
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa Clinical research trials and Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa. Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa clinical trial. Participants typically obtain the most effective healthcare available for their Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa  Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
For Condition: Retinitis Pigmentosa
Status: Recruiting
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: Vitamin A is an essential nutrient that cannot be made in the body, and it is difficult to get significant amounts of vitamin A from food sources. The purpose of this study is to determine whether taking an oral vitamin A supplement will improve the retinal function of patients with retinitis pigmentosa (RP). Patients with RP progressively lose the ability to read fine print and perceive color. Fifteen participants age 18 and older who have various types of RP will participate in this study. They will take vitamin A capsules (doses of 15,000 IU to 50,000 UI) daily for 4 weeks; then they will switch to a lower dose for an additional 2 weeks. At an initial visit to the Clinical Center, participants will undergo a medical history, physical exam, blood work, and an eye exam that includes an electroretinogram. During each of five follow-up visits, doctors will measure the amount of vitamin A in participants' blood to see if it increases over time. The follow-up visits will take place approximately every 2 weeks for approximately 2.5 months.
Details: Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States(1). Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP(2). The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness(3). Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years(4). The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 5 participants will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphery, 10-12; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All participants must meet the following criteria to participate in the study. 1. Men and women age 18 years of age and older. 2. Diagnoses of typical RP of all genetic subtypes (simplex, autosomal dominant, autosomal recessive, and X-linked), as determined primarily by abnormally reduced ERG rod response amplitudes that are relatively more affected than cone ERG amplitudes. 3. Participants in whom flicker ERG can be measured reliably (standard flicker ERG amplitude greater than 2 mV). 4. Willingness to use contraception for the duration of the study. 5. Understood and signed consent. EXCLUSION CRITERIA: Participants with the following conditions will be excluded from study. 1. Participants with syndromic RP (i.e., Ushers syndrome). 2. Have abnormal liver function (greater ULN ALT, AST, Alkaline Phosphate, or Total Bilirubin). 3. Hematocrit greater than 1.5 x ULN 4. Have abnormal kidney function (greater than1.5 mg/dl serum creatinine). 5. Currently or has taken vitamin A supplementation within 6 months of the first screening visit. 6. Is pregnant or lactating (due to evidence that sugests excessive intake of vitamin A could be tertogenic in humans and affect the content of breast milk). 7. Currently or has taken greater than 400 IU/day of vitamin E supplementation within 6 months of enrollment. 8. Vitamin A serum level exceeding 150 mg/dL.
Total Enrollment: 5
Location and Contact Information:
National Eye Institute (NEI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030255; 03-EI-0255
Study Start Date: July 17, 2003
Record last reviewed: July 14, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065455
Other Retinitis Pigmentosa Studies:
1. Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
2. Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
3. S tudy of Usher Syndromes, Type 1 and Type 2
4. Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
5. Study of Docosahexaenoic Acid (DHA) Supplementation in Patients with X-Linked Retinitis Pigmentosa
Related Studies:
Other Retinitis Pigmentosa Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
|
|
|
|
|
|
|
|
